Global Oral Proteins and Peptides Market Report and Forecast 2024-2032

Global Oral Proteins and Peptides Market Outlook

The global oral proteins and peptides market size was valued at USD 2.52 billion in 2023, driven by increasing prevalence of diabetes and gastrointestinal disorders across the globe. The market size is anticipated to grow at a CAGR of 14.5 % during the forecast period of 2024-2032 to achieve a value of USD 8.3 billion by 2032.

Oral Proteins and Peptides: Introduction

The Oral Proteins and Peptides market involves the development and distribution of protein and peptide-based therapeutics designed for oral administration. These biomolecules offer potential treatments for various diseases, including diabetes, gastrointestinal disorders, and others. Oral delivery is preferred for its convenience and non-invasive nature but poses challenges due to protein and peptide degradation in the digestive system. Advances in drug formulation and delivery technologies aim to overcome these barriers, enhancing bioavailability and therapeutic effectiveness.

Key Trends in the Global Oral Proteins and Peptides Market

Efforts are being intensified to develop efficient delivery mechanisms to protect proteins and peptides from digestive enzymes and improve absorption in the gastrointestinal tract. Technologies like nanoparticle encapsulation and permeability enhancers are gaining traction.

Initially concentrated in areas like diabetes and gastrointestinal disorders, the scope of oral proteins and peptides is broadening to include a wider range of therapeutic areas, including autoimmune diseases and cancers.

The convenience and non-invasive nature of oral administration are in line with the increasing demand for patient-centric treatment options, driving research and acceptance of oral proteins and peptides.

Pharmaceutical companies are increasingly collaborating with biotech firms and academic institutions to leverage expertise in drug development and commercialization, accelerating the introduction of innovative products.

Regulatory bodies are acknowledging the potential of oral proteins and peptides, leading to streamlined pathways for approval, especially for treatments addressing unmet medical needs.

The ease of administration and storage of oral formulations align with global health goals to improve access to essential medicines, particularly in low-resource settings.

Global Oral Proteins and Peptides Market Segmentation

Market Breakup by Drug Type

• Plecanatide
• Linaclotide
• Octreotide
• Calcitonin
• Insulin

Market Breakup by Application

• Gastric and Digestive Disorders
• Bone Diseases
• Diabetes
• Hormonal Disorders

Market Breakup by End User

• Hospitals
• Ambulatory Surgical Centre
• Clinics

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Global Oral Proteins and Peptides Market Overview

In North America, the oral proteins and peptides market is propelled by advanced biotechnological research, a strong pharmaceutical industry, and substantial healthcare spending. The region leads in innovative drug delivery system developments and patient-centric drug design, focusing on improving the bioavailability and efficacy of oral protein and peptide therapeutics. There's also a significant emphasis on regulatory compliance and intellectual property rights, fostering a competitive and dynamic market environment.

Europe's market benefits from a robust healthcare research infrastructure, stringent regulatory standards, and a focus on advanced pharmaceutical innovation. The region shows a strong commitment to developing novel drug delivery technologies, including oral proteins and peptides. Collaborative research efforts, supported by public and private funding, contribute to the exploration of new treatments for chronic diseases. The market is also influenced by policies aimed at ensuring patient safety and high-quality pharmaceutical products.

The market in the Asia-Pacific region is rapidly growing, driven by increasing healthcare investments, a rising prevalence of chronic diseases, and improvements in biopharmaceutical research capabilities. Countries like China, India, and Japan are becoming significant players in the pharmaceutical industry, focusing on both innovative research and the production of generic drugs. The market's growth is further fueled by a growing middle class, increasing healthcare awareness, and expanding access to healthcare services.

Global Oral Proteins and Peptides Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

• Novo Nordisk A/S
• Synergy Pharmaceuticals Inc.
• Chiasma Inc.
• Tarsa Therapeutics Inc.
• Biocon Limited
• Generex Biotechnology Corp.
• AstraZeneca PLC
• Proxima Concepts Limited
• Oramed Pharmaceuticals Inc.
• Allergan Plc.
• Generex Biotechnology Corp.
• Hoffmann-La Roche
• Sanofi
• Bristol-Myers Squibb Company
• Hovione

This product will be delivered within 5-7 business days.